Home > Insider Trading > Filing (0001209191-22-054855)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1601830	Recursion Pharmaceuticals Inc.	RXRX	Biological Products, (No Disgnostic Substances) (2836)	464099738

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1856414	Marriott Tina Larson	41 S. Rio Grande Street Salt Lake City UT 84101	President And Coo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2022-10-27	16,000	$1.06	221,107	No	4	M	Direct
Class A Common Stock	Disposition	2022-10-27	16,000	$10.72	205,107	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (Right to Buy)	Disposition	2022-10-27	16,000	$0.00	16,000	$1.06

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
586,000		2028-07-22	No	4	M	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Remaning Holdings	Nature of Ownership
Class A Common Stock	Stock Option (Right to Buy)	$11.40		2032-02-04	159,226	Direct
Class A Common Stock	Stock Option (Right to Buy)	$11.40	2022-02-04	2032-02-04	4,784	Direct
Class A Common Stock	Stock Option (Right to Buy)	$2.47		2030-12-30	150,000	Direct

Expiration Date	Remaning Holdings	Nature of Ownership
2032-02-04	159,226	Direct
2032-02-04	4,784	Direct
2030-12-30	150,000	Direct

Footnotes

Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person.
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.35 to $11.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.